Xintela

Xintela uses the stem cell marker integrin α10β1 to develop stem cell therapies such as XSTEM and EQSTEM, and targeted cancer therapies via Targinta.

Xintela uses the stem cell marker integrin α10β1 to develop stem cell therapies (XSTEM and EQSTEM) and targeted cancer therapies through Targinta.

Latest news from Xintela: press releases and financial reports, the Xintelling newsletter, videos, Xintela in the news and events.

The page shares Xintela’s latest news, including press releases, financial reports, the Xintelling newsletter, videos, media coverage, and events.

About Targinta, Xintela’s subsidiary developing antibodies and ADCs against integrin α10β1 for aggressive cancer. History, management, board, partnering.

The page provides stock information, financial reports, calendars, analyses, and corporate governance for Xintela AB (publ), listed on Nasdaq First North Growth Market (XINT).

The page describes Targinta, a subsidiary of Xintela, which develops antibodies and antibody-drug conjugates targeting integrin α10β1 for aggressive cancers. It covers history, leadership, board, and partnerships.

The page lists Xintela AB’s contact details at Medicon Village, Lund, including phone, email, CEO, CFO, and career information.

Xintela’s stem cell therapy research explores new treatments for severe conditions such as arthritis and chronic wounds.

Xintela’s research and development in stem cell therapy is blazing a new path for the treatment of severe diseases such as osteoarthritis and

Xintela secures a U.S. patent for **XSTEM**, a regenerative treatment targeting chronic wounds and skin defects. Preclinical data demonstrate enhanced healing and scar reduction, while clinical trials are underway for hard-to-treat ulcers and burns. The patent bolsters intellectual property protection in the U.S. market.

Apr 2026Regen Report - B2B Publication on Regenerative Medicine and Stem CellsNews article

Xintela reports that its 2025 clinical study of **XSTEM** for knee osteoarthritis showed **safe, effective pain reduction** and **improved joint function**. The treatment also **halted cartilage degradation** and **enhanced cartilage and bone structure** in participants. The company continues to build on this momentum as it advances toward future development.

Mar 2026BiostockNews article

Xintela finalizes a Phase I/IIa trial testing its stem cell therapy **XSTEM** in six patients with chronic venous leg ulcers. The study assesses safety and tolerability, with results slated for release by late May. Recruitment challenges limited the patient cohort.

Feb 2026BiostockNews article

Xintela develops cell and antibody therapies targeting integrin α10β1, a proprietary marker for selecting mesenchymal stem cells (MSCs). The company’s XSTEM platform leverages this technology to produce homogeneous, high-quality MSCs for therapeutic use. Its subsidiary, Targinta, applies the same marker to develop antibodies for treating aggressive tumors with limited treatment options.

Nov 2025BiostockNews article